Greetings, and welcome to the Biostage Investor Update Call.
At this time, all participants are in a listen-only mode. Due to the fact that the company is in the SEC-mandated quiet period, there will not be a question and answer period today.
As a reminder, this conference is being recorded. Let me now introduce your host, Peter A. Pellegrino.
Thank you, sir. You may begin.
Thank you. Good morning.
This is Peter Pellegrino, Interim Vice President of Finance.
On the call with me today is David Green, our Interim Chief Executive Officer. Before I turn it over to David, let me review the company's forward-looking statements. In our discussion today, we will make statements that constitute forward-looking statements.
Our actual results and performance may differ materially from what we have previously projected due to the risks and uncertainties, including those detailed in our annual report on Form 10-K for the year ended December 31, 2021, and our other public filings, including our Form S-1 filed with the Securities and Exchange Commission on June 21, 2022.
Any forward-looking statements, including those related to our future results and activities, represent our estimates as of today and should not be relied upon as representing our estimates at any subsequent day.
Additionally, any material, financial or statistical information presented in the call, which are not included in our press release, will be archived and available in the investor section of our website under Events and Presentations.
I would like to remind everyone that we are currently in the SEC-mandated quiet period and all relevant disclosures about the company are included on Form S-1. Hence, we will not be taking any questions on this call.
Now, I'll turn it over to David.
Thank you, Peter, and welcome everyone to this quarterly conference call for Biostage to discuss earnings and related matters.
Let me first start with business highlights of the Q2. First, on May 16, 2022, Biostage completed a private placement of its common shares with new and existing investors, which generated net proceeds of approximately $5.1 million.
A significant portion of these funds will be used to accelerate the clinical development of Biostage's lead product candidate, the Cellspan Esophageal Implant. Second, on April 27, Biostage executed a settlement agreement which resolves all claims relating to the litigation against the company and its former parent, Harvard Bioscience or HBIO.
The settlement resulted in the dismissal with prejudice of the wrongful death claim, and Biostage did not admit any fault or liability in connection with the claim.
In relation to the litigation, settlement and related legal expenses, the company incurred approximately $5.9 million of costs, excuse me, of which approximately $1.3 million remain unpaid as of June 30th, 2022.
With respect to these costs, the company is required to either pay such costs directly or indemnify HBIO as to such amounts it pays. By the end of Q2, HBIO had paid an aggregate amount of $4.0 million.
Biostage settled this obligation to HBIO by issuing $4.0 million of Series E convertible preferred stock to Harvard Bioscience.
The preferred stock automatically converts to common stock at a public offering of common stock or other financing as defined in the preferred issuance agreement.
Until conversion, the preferred stock carries an 8% annual dividend, which is paid in additional shares. It is not paid in cash.
The preferred stock has no voting rights until converted to common shares.
Third, on June twenty-first, the company filed a registration statement on Form S-1 with the SEC and also filed an application to list the company's shares for trading on the Nasdaq exchange.
We are currently in the SEC-mandated quiet period and all relevant disclosures about the company are included in the Form S-1. I will now turn this over to Peter to review the financial results of Q2. Peter.
Thank you, David.
I want to briefly cover the highlights of our Q2 financial results. Our net loss was approximately $1.3 million, or $0.12 per basic and diluted share for the quarter ended June 30, 2022.
Those figures include approximately $0.3 million of non-cash charges for share-based compensation and depreciation expenses. As of June 30, 2022, we had cash on hand of approximately $4.6 million and had no debt.
We used approximately $1.1 million in cash for operations during the quarter.
During the quarter ended June 30, 2022, we received aggregate net proceeds of approximately $5.1 million from the private placement.
Based on our current operating plan and giving consideration to this cash infusion, we expect that our current cash will be sufficient to fund our operating expenses and capital expenditure requirements into the Q2 of 2023.
Thank you, Peter.
Due to this SEC-mandated quiet period, we will not be taking questions on this call.
Thank you for your participation today.
We look forward to making Biostage a success for both its patients and its shareholders.
Thank you and have a good day.
Thank you, ladies and gentlemen.
This does conclude today's teleconference.
You may disconnect your lines at this time and thank you for your participation and have a great day.